MARKET OVERVIEW

The Germany pharmaceutical market size reached USD 64.7 Billion in 2024 and is forecast to grow to USD 119.4 Billion by 2033. The market is expected to grow at a CAGR of 6.50% during the forecast period of 2025-2033. This growth is driven by factors such as the aging population, increasing healthcare expenditure, adoption of generic drugs, and expansion of biopharmaceuticals. Germany holds the position of the largest pharmaceutical market in Europe and ranks fourth globally.

STUDY ASSUMPTION YEARS

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

GERMANY PHARMACEUTICAL MARKET KEY TAKEAWAYS

• Current Market Size: USD 64.7 Billion in 2024
• CAGR: 6.50% during 2025-2033
• Forecast Period: 2025-2033
• Germany is the largest pharmaceutical market in Europe and ranks fourth globally following the US, China, and Japan.
• Growing aging population with 18.6 million people aged 65 and above in 2022 drives demand for geriatric medicine and chronic disease treatments.
• Increasing healthcare expenditure, which rose to 474.1 billion euros in 2021, supports higher pharmaceutical sales and R&D investment.
• Expansion and focus on biotech-driven therapies, including genetic engineering and mRNA platforms, are shaping the biopharmaceutical market.
• Surge in non-prescription (OTC) drug sales driven by consumer self-care trends, greater health awareness, and aging population.

Sample Request Link: https://www.imarcgroup.com/Germany-Pharmaceutical-Market/requestsample

MARKET GROWTH FACTORS

The pharmaceutical market of Germany is expected to grow because of its aging population. According to a 2023 National Library of Medicine report, there were 18.6 million people age 65 years or older in Germany in 2022. There were also 6.1 million people who were 80 years or older. The older age group has induced drug companies to introduce medications that can easily be swallowed, have fewer side effects and consider the organ responses altered by age (e.g. liver, kidney). Cardiovascular disease, diabetes, arthritis, and neurodegenerative diseases are all typical of the older age group. Medications that delay and/or treat the disease and/or the symptoms of the disease are required. About preventive medicines and vaccines for osteoporosis, dementia and cancers are being developed to ensure that aging remains healthy.

For 2021, Federal Statistical Office of Germany (Destatis) reported that healthcare expenditure in Germany totaled 474.1 billion euros. More healthcare spending allows better access to healthcare and medicines. This creates more need for pharmaceutical goods in Germany. Expenditure for healthcare increases the availability of diagnosis and prescribing a drug, and a greater revenue base allows companies to spend more on research and development (R&D) into drugs fulfilling unmet clinical needs. Thus, the German Pharmaceutical Industry Association (BPI) stands by continuous increases in R&D expenditures with growth for the industry.

Biotechnology is important for the growth of the German pharmaceutical market. BioNTech's COVID-19 vaccination was a success. Genetic engineering, mRNA technology, and personalized medicine have since attracted large investment in particular within oncology, neurology, and autoimmune diseases. Existing companies partner with start-ups, research institutions, and technology-based companies, while the federal government promotes biotechnology growth through grants and regulatory assistance. As reimbursement of and clinical experience with biotech therapy have grown, biologics have gone from being seen as experimental to being the standard in next-generation drug development.

MARKET SEGMENTATION

Type Insights:

• Pharmaceutical Drugs: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs
• Biologics: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines

Nature Insights:

• Organic
• Conventional

Region Insights:

• Western Germany
• Southern Germany
• Eastern Germany
• Northern Germany

REGIONAL INSIGHTS

Western Germany is identified as a major regional market in the Germany pharmaceutical sector. The report provides a comprehensive analysis of all key regions—Western Germany, Southern Germany, Eastern Germany, and Northern Germany—though specific regional statistics, such as market share or CAGR, are not detailed in the source. Western Germany's prominence reflects its significant contribution to the overall pharmaceutical market in the country.

RECENT DEVELOPMENTS & NEWS

In March 2025, Isotopia launched Isoprotrace in Germany, a radiopharmaceutical for PET imaging of prostate cancer, distributed exclusively by DSD Pharma. This launch includes preparations for Gallium-68 Gozetotide injections targeting PSMA-positive lesions and Lutetium-177 Chloride n.c.a., enhancing cancer diagnosis and treatment in nuclear medicine.

In October 2024, LEO Pharma launched Anzupgo (delgocitinib) cream, the first global debut for adults with moderate to severe chronic hand eczema unresponsive to corticosteroids. Germany is the first to offer this treatment addressing inflammation and skin barrier issues.

On May 22, 2024, Boehringer Ingelheim and OSE Immunotherapeutic expanded their collaboration to develop treatments for cancer and cardio-renal-metabolic diseases.

In March 2024, Bayer and Aignostics GmbH announced a strategic collaboration on AI-powered approaches in precision oncology drug research and development, emphasizing innovation in German pharmaceuticals.

KEY PLAYERS

• Bayer
• Boehringer Ingelheim
• Merck KGaA

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.